Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Japan’s First SGLT-2 Inhibitor Suglat Approved: Astellas
January 20, 2014
- Otsuka Files Abilify Once-Monthly Injectable in Japan
January 17, 2014
- Alcon Japan Merges with CIBA Vision
January 17, 2014
- MTPC Files Telavic for Chronic Hepatitis C Genotype 2
January 17, 2014
- FDA Raises Concerns about Ranbaxy’s India Plant with Form 483
January 16, 2014
- Japan Added as Mogamulizumab PIII Study Site for CTCL Patients: Kyowa Kirin
January 16, 2014
- Takeda to Sell BIKEN Varicella Vaccine from February
January 16, 2014
- Swiss Novartis to “Fully Address” Flaws Leading to Criminal Complaint Filing
January 16, 2014
- Seikagaku Confirms Winning in Gel-One Patent Infringement Lawsuit Following Genzyme’s Withdrawal of Appeal
January 16, 2014
- Special Drug Use-Result Survey for Plavix Finds 0.19% Incidence of Cerebral Hemorrhage in Cerebral Infarction in Acute Phase
January 16, 2014
- Takeda Appoints Former GSK Exec as Head of CNS Drug Discovery Unit
January 15, 2014
- Shionogi Inc., Hisamitsu Unit to Copromote Hot Flashes Drug in US
January 15, 2014
- Daiichi Sankyo, 2 US Startups to Collaborate on Research of Academia-Oriented Seeds
January 14, 2014
- Ethical Drug Sales Up 0.8% in November Due to New Drug Launches and Lifting of 14-Day Prescription Limit: Crecon Report
January 14, 2014
- Pharma Biz Leaders Say New Price Cut Rule for Long-Listed Products a Painful Blow
January 10, 2014
- Daiichi Sankyo Submits NDA for Edoxaban in US
January 10, 2014
- Novartis Issues Apologies after Complaint Filing over Diovan, Vows Cooperation with Authorities
January 10, 2014
- Proposal to Reduce Basic Fees for Medical Institutions with Low Price Agreement Rates Could Have Big Impact: Mr Kono of Toho Pharmaceutical
January 10, 2014
- New IFN-Free Oral Drugs for Chronic Hepatitis C Could Create New Market
January 10, 2014
- MTPC Sets Up Medway Business Management Office Eyeing Resumption of Medway Injection Production
January 9, 2014
ページ
AAV (adeno-associated virus) gene therapies are moving beyond rare diseases into more prevalent conditions, with neovascular, or wet, age-related macular…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…